Five patients known to be previously hypertensive but not currently receiving anti-hypertensive medications were studied for a total of twenty-six administrations of electroconvulsive therapy. Patients randomly received sublingual nifedipine 10 mg, 20 minutes prior to half of their treatments, and for the remaining treatments acted as their own controls. The use of nifedipine resulted in significant attenuation of the blood pressure response to therapy. Systolic pressure increase was 24 mmHg (SD 14) versus 62 mmHg (SD 24) (P < 0.01). There was no difference in heart rate between the two groups. It is concluded that nifedipine reduces the pressor response to electroconvulsive therapy in individuals with a history of hypertension.
The administration of electroconvulsive therapy (ECT) can provoke an acute rise in systemic blood pressure, especially in patients with a history of hypertension. 1 Several methods of attenuating this hypertensive response have been previously described. [2] [3] [4] We report our experience with the use of sublingual nifedipin~ administered prior to ECT in a group of five severely depressed patients, all of whom had been documented in the past as hypertensive.
METHODS
The study was approved by our institutional review committee and over a four-month period, five patients (three males, two females) scheduled to receive ECT gave informed consent for participation. These five patients had all been documented and treated for hypertension in the previous two years, yet prior to admission had achieved sufficient blood pressure control to permit withdrawal of antihypertensive therapy. Our protocol called for the inclusion of such patients only if no antihypertensive therapy had been administered for at least two weeks prior to therapy. To be included in the study patients could not be receiving mood-altering drugs of any kind as it was felt these might modify the haemodynamic responses to ECT. The average age of the patients was 64 years (range 57-75 years) and average weight 68 kg (range 59-84 kg). A diagnosis of severe depression was present in all patients. The convulsive parameters used were identical for all treatments -pulse frequency 40 Hz, pulse width 1.5 msec and pulse duration 2 sec. Each patient acted as his or her own control, and was randomly allocated to receive nifedipine 10 mg sublingualy 20 minutes prior to therapy on half the occasions in which he or she was studied.
The nifedipine was administered by placing the capsule in a 3 ml syringe, piercing the capsule with a 22 gauge needle via the syringe orifice and expelling the contents by applying firm pressure on the plunger. 5 All patients were monitored by electrocardiogram (ECG) lead CM5, a blood pressure cuff using the Korotkov sound method and a precordial stethoscope. Anaesthesia consisted of consecutive injections of atropine sulphate 6 Ilg/kg, methohexitone 1.5 mg/kg and succinylcholine 0.7 mg/kg. Ventilation was controlled by mask with 100% oxygen. Measurements of pulse rate and blood pressure (BP) were taken prior to nifedipine administration, immediately prior to anaesthesia and then every 30 seconds for five minutes after the completion of the convulsion. Patients were admitted to a recovery room for at least 30 minutes after the completion of therapy. Data were analysed by paired t-test. All results are presented as mean with standard deviation in parenthesis.
RESULTS
A total of 26 treatments were administered, thirteen with and thirteen without nifedipine. Before induction, systolic blood pressures were lower in the nifedipine treated group, 129 mmHg (SD 18) as opposed to 140 mmHg (SD 18) in the group without nifedipine.
(P < 0.05). The increase in systolic blood pressure in the absence of nifedipine was 62 mmHg (SD 24). In the same patients receiving nifedipine, the increase in systolic pressure was 24 mmHg (SD 14, P< 0.001). There was no statistically significant difference in pulse rates in the presence of or absence of nifedipine. No episodes of hypotension occurred either immediately after administration of nifedipine, in the recovery room or afterwards in the ward. The results are summarised in Table 1 . DISCUSSION ECT is used primarily in the treatment of depression, schizophrenia and mania. 1 A typical course of therapy involves ten to fourteen treatments administered over a three-to-four week period. The application of the electroshock provokes a biphasic autonomic response, in which an initial parasympathetic discharge is followed by a period of sympathetic hyperactivity.6,7 The usual heart rate response to therapy is of the order of 130-190 beats per minute, with elevations of systolic and diastolic pressure of 10-15 mmHg and 10-30 mmHg respectively.6,7 Egbert 8 found hypertension greater than 120% of control to be present for a mean period of 160 seconds. Patients who are hypertensive often show greater ECTrelated increases in blood pressure than those who are normotensive. 1 Cardiac arrest is the leading cause of death 1 and as early as 1961 it was reported that patients with coronary artery disease were at greater risk. 9 More recent work has produced conflicting results concerning the safety of ECT in high risk patients. The work of Gerring and Shields 10 demonstrated a much higher risk of ECT-induced myocardial ischaemia and/or arrhythmias in patients with underlying cardiovascular disease. On the other hand, Dec et al. 11 were unable to show a higher incidence of complications in a similar group of patients. They in part attributed this difference to intensive pretreatment preparation. Nevertheless, attempts to modify the autonomic response to ECT, particularly in hypertensive patients would seem reasonable.
Many pharmacological agents have been used in attempts to modify this response. Previous work has described the use of sodium nitroprusside,2 clonidine,2 nitroglycerin ointment 3 and propranolol in combination with hydralazine. 4 The use of calcium channel blocking agents in this manner has not previously been described but may be of particular value in patients at risk from myocardial ischaemia. The calcium channel blocker, nifedipine, inhibits the transmembrane influx of calcium ions into cardic muscle and smooth muscle. The contractile process is dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. It is this calcium influx which is selectively inhibited by calcium channel blockers. Nifedipine has been predominantly used for the treatment of angina. It dilates main coronary arteries and arterioles and is an inhibitor of coronary artery spasm. Nifedipine also reduces systemic pressure by dilating peripheral arterioles. Nifedipine becomes detectable in serum ten minutes after oral administration and peak blood levels occur in about 30 minutes; it remains detectable for up to six hours. Results of pharmacodynamic studies show that maximal hypotensive effects occur between 30 and 60 minutes after administration by either oral or sublingual routeY Peak serum levels of nifedipine are reached 25 minutes after tablets, which are initially bitten, are ingested and 35 minutes after sublingual administration. 12 Although the drug appeared in plasma slightly earlier after sublingual dosing, administration by the oral route results in a greater rate of increase in drug levels and a more rapid attainment of peak levels. 12 From recent studies it appears that favourable therapeutic results obtained with We presume that the major contribution to nifedipine absorption occurred via subsequent swallowing of the drug over the following twenty minutes. Nifedipine pretreatment did not result in any significant difference in the heart rate response to therapy. We conclude that pretreatment with sublingual nifedipine should be considered in .those individuals in whom attenuation of the hypertensive response to electroconvulsive therapy is desirable. the use of sublingual nifedipine in the treatment of cardiovascular crises are probably due to swallowing of the drug. Van Harten recommends that if a fast onset of 11. action of nifedipine is desired, the patient should be instructed to bite a capsule and swallow the contents with water. 13 Our results demonstrate an effective reduction in the hypertensive response to ECT when nifedipine 10 mg is administered sublingually twenty minutes prior to therapy. 
